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Objectives This study sought to examine the role of lipoprotein-associated phospholipase A2 (Lp-PLA2/PLA2G7) in human
inflammation and coronary atherosclerosis.
Background Lp-PLA2 has emerged as a potential therapeutic target in coronary heart disease. Data supporting Lp-PLA2 are
indirect and confounded by species differences; whether Lp-PLA2 is causal in coronary heart disease remains in
question.
Methods We examined inflammatory regulation of Lp-PLA2 during experimental endotoxemia in humans, probed the
source of Lp-PLA2 in human leukocytes under inflammatory conditions, and assessed the relationship of varia-
tion in PLA2G7, the gene encoding Lp-PLA2, with coronary artery calcification.
Results In contrast to circulating tumor necrosis factor-alpha and C-reactive protein, blood and monocyte Lp-PLA2 mes-
senger ribonucleic acid decreased transiently, and plasma Lp-PLA2 mass declined modestly during endotoxemia.
In vitro, Lp-PLA2 expression increased dramatically during human monocyte to macrophage differentiation and
further in inflammatory macrophages and foamlike cells. Despite only a marginal association of single nucleo-
tide polymorphisms in PLA2G7 with Lp-PLA2 activity or mass, numerous PLA2G7 single nucleotide polymor-
phisms were associated with coronary artery calcification. In contrast, several single nucleotide polymorphisms
in CRP were significantly associated with plasma C-reactive protein levels but had no relation with coronary ar-
tery calcification.
Conclusions Circulating Lp-PLA2 did not increase during acute phase response in humans, whereas inflammatory macro-
phages and foam cells, but not circulating monocytes, are major leukocyte sources of Lp-PLA2. Common genetic
variation in PLA2G7 is associated with subclinical coronary atherosclerosis. These data link Lp-PLA2 to athero-
sclerosis in humans while highlighting the challenge in using circulating Lp-PLA2 as a biomarker of Lp-PLA2
actions in the vasculature. (J Am Coll Cardiol 2012;59:764–72) © 2012 by the American College of Cardiology
Foundation
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eLipoprotein-associated phospholipase A2 (Lp-PLA2) has
merged as a potential therapeutic target in coronary heart
isease (CHD) and phase III clinical trials are underway.
upporting evidence includes apparent atherogenic bio-
hemical properties; Lp-PLA2 cleaves oxidized phosphati-
ylcholine on modified low-density lipoprotein (LDL),
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clinical and clinical trials have been carried out (5–7).
and Endocrine Research Center (P20-DK 019525) award (both from the National
Institute of Health to the University of Pennsylvania), and P50 HL-083799-SCCOR
Project award from the National Institute of Health (to Dr. Reilly). GlaxoSmithKline
provided research grant support for measurement of Lp-PLA2 mass and activity. Drs.
Rader and Reilly received research grant support from GlaxoSmithKline. Employees
of GlaxoSmithKline did not contribute to study design, data interpretation, and
editing of the report. All other authors have reported that they have no relationships
relevant to the contents of this paper to disclose.Manuscript received May 13, 2011; revised manuscript received October 31, 2011,
accepted November 16, 2011.
ii
a
t
l
c
t
a
l
p
L
t
c
h
c
r
V
t
(
h
c
c
M
C
t
(
s
A
a
r
p
b
a
p
c
i
u
d
T
m
a
l
m
(
r
t
n
P
765JACC Vol. 59, No. 8, 2012 Ferguson et al.
February 21, 2012:764–72 Human Translation of Lp-PLA2However, whether Lp-PLA2 is causal and whether its
nhibition will prevent CHD events remain undetermined.
Data for Lp-PLA2 in human atherosclerosis remain
ndirect and confounded by species differences in physiology
nd actions. Lp-PLA2 circulates in blood bound to lipopro-
eins that modulate its actions. In rodents, Lp-PLA2 is
carried mostly on high-density lipoprotein particles,
whereas in humans, the enzyme is bound to LDL particles.
Thus, confounding may be particularly marked for plasma
Lp-PLA2 relative to other inflammatory markers, as regu-
ation of atherogenic lipoproteins is a major influence on
irculating Lp-PLA2 levels and activity (8). Indeed, whether
circulating Lp-PLA2 is associated with CHD beyond a complete
assessment of atherogenic lipoproteins remains uncertain (9).
Arterial Lp-PLA2 biosynthesis by macrophages and foam
cells, rather than circulating levels or activity, may deter-
mine its atherogenicity (10). Lp-PLA2 expression within
he necrotic core and surrounding macrophages of vulner-
ble and ruptured plaques, compared with less-advanced
esions, is increased (11), suggesting a potential role in
romoting plaque instability. The extent to which human
p-PLA2 is regulated in circulation by systemic inflamma-
tion, however, versus locally controlled in arterial
macrophage-foam cells is uncertain. Further, lesion biosyn-
thesis is difficult to measure in humans, limiting our ability
to monitor Lp-PLA2 activity in disease-relevant tissue and
o assess vascular efficacy of pharmacological inhibition.
In this report, we examined inflammatory regulation of
irculating Lp-PLA2 during experimental endotoxemia in
umans, probed the source of Lp-PLA2 in human leuko-
ytes under inflammatory conditions, and determined the
elationship of genetic variation in phospholipase A2, group
II (PLA2G7), the gene encoding Lp-PLA2, to coronary
artery calcification (CAC) as well as plasma levels of
Lp-PLA2 mass and activity. We found that, unlike blood
umor necrosis factor (TNF)-alpha and C-reactive protein
CRP), circulating Lp-PLA2 did not increase during the
acute phase response in humans; that inflammatory macro-
phages and foam cells, but not circulating or ex vivo
monocytes, are primary leukocyte sources of Lp-PLA2; and
that common genetic variation in PLA2G7 is associated
with subclinical coronary atherosclerosis. These data link
Lp-PLA2 to atherosclerosis in humans while providing a
uman physiological context for the difficulty in using
irculating Lp-PLA2 as a biomarker of disease or pharma-
ological efficacy in atherosclerosis.
ethods
linical studies. HUMAN ENDOTOXEMIA. Healthy volun-
eers on no medications and no significant medical history
n  32, 50% women; mean age 25.7  3.90 years) were
tudied as described previously (12,13) and in the Online
ppendix. Serial blood samples were collected before and
fter intravenous bolus infusion of 3 ng/kg U.S. standard ueference endotoxin and were
repared for plasma, whole-
lood ribonucleic acid (RNA)
nd monocyte RNA (12).
GENETIC ASSOCIATION STUDIES.
The PennCAC (Penn Coronary
Artery Calcification) resource in-
cluded European-ancestry subjects
recruited to 3 separate studies at
the University of Pennsylvania: the
SIRCA (Study of Inherited Risk
of Coronary Atherosclerosis) (n
799), the PDHS (Penn Diabetes
Heart Study) (n  782), and the
PAMSyN (Philadelphia Area Met-
abolic Syndrome Network) (n 
480). These studies are described in
detail previously (14,15) and in the
Online Appendix. In each study,
subjects with clinical atherosclerotic
cardiovascular disease were ex-
cluded. PLA2G7 single nucleotide
polymorphisms (SNPs) were geno-
typed in all 3 studies. Plasma Lp-
PLA2 mass and activity data were
available in SIRCA and PDHS. Global CAC scores were
determined by electron beam tomography (Imatron, San Fran-
cisco, California) according to the method of Agatston et al.
(16). For all human studies described, the University of
Pennsylvania Institutional Review Board approved each study,
and written informed consent was provided by all participants.
Laboratory methods. HUMAN MONOCYTE, MACROPHAGE,
AND FOAM CELL STUDIES. Humanmonocyte isolation, macro-
hage (M1 and M2 phenotype) differentiation (17), and “foam
ell” preparation were performed as described elsewhere (12) and
n the Online Appendix. Experiments were performed in batches
sing freshly isolated monocytes, macrophages, and foam cells
erived from the same human volunteer.
PLASMA LP-PLA2, INFLAMMATORY, AND METABOLIC MARKERS.
Plasma and cell-media levels of Lp-PLA2 mass and activity,
NF-alpha, and CRP, as well as lipid and biochemical
arkers were measured as described elsewhere (13,14,18)
nd in the Online Appendix.
REAL-TIME QUANTITATIVE PCR AND EXPRESSION
QUANTITATIVE TRAIT LOCUS ANALYSIS. Whole-blood, iso-
ated circulating monocyte, and human cultured monocyte,
acrophage, and foam cell messenger ribonucleic acid
mRNA) were subjected to quantitative polymerase chain
eaction (PCR) using primers and probes (Applied Biosys-
ems 7300 Real-Time PCR System, Foster City, Califor-
ia) as previously described (12) for measurement of Lp-
LA2, TNF-alpha, and beta-actin mRNA (Online
Appendix). The relative quantitation 2-(Ct) method was
Abbreviations
and Acronyms
CAC  coronary artery
calcification
CHD  coronary heart
disease
CRP  C-reactive protein
CT  cycle threshold
eQTL  expression
quantitative trait locus
LDL  low-density
lipoprotein
Lp-PLA2  lipoprotein-
associated phospholipase A2
LPS  lipopolysaccharide
mRNA  messenger
ribonucleic acid
PCR  polymerase chain
reaction
RNA  ribonucleic acid
SNP  single nucleotide
polymorphism
TNF  tumor necrosis
factorsed to determine fold-change from baseline (19). Explor-
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Human Translation of Lp-PLA2 February 21, 2012:764–72atory expression quantitative trait locus (eQTL) analysis is
described in the Online Appendix.
GENOTYPING. As described previously (20) and in the Online
Appendix, PennCAC participants were genotyped using the
ITMAT Broad Care CARDIOVASCULAR DISEASE
candidate gene array, which surveys50,000 SNPs in2,000
andidate genes (21). SNP data for PLA2G7 (n  19) and
RP (n  16) were selected for the present analysis.
tatistical analysis. The effect of endotoxemia on plasma
p-PLA2 mass and activity, TNF-alpha, and CRP, as well
s whole blood and monocyte mRNA was tested by
epeated-measures analysis of variance. Analysis of variance
as applied also to in vitro cell data. Post hoc t tests were
sed to compare specific time points and treatments. We
bserved heterogeneity of variance in several variables fol-
owing lipopolysaccharide (LPS) challenge, which was to be
xpected given the known variation in responses to endo-
oxin. We tested for homogeneity of variance using Levene
est, and in cases where the assumption of homogeneity of
ariance was violated, we confirmed whether the group
ifferences were significant using Tamhane post-hoc test.
In PennCAC, CAC scores were transformed by the natural
og after adding 1, [Ln(CAC  1)], to correct for skewed
istribution. This variable was used as the outcome in a linear
egression model, with PLA2G7 and CRP SNPs, adjusting for
ge, sex, and age–sex interaction. For linear regression analysis
f SNP associations with plasma proteins, Lp-PLA2 mass and
Figure 1 Human Endotoxemia Does Not Induce Circulating Lp-P
Endotoxemia (3 ng/kg lipopolysaccharide [LPS] intravenously) markedly increased
(p  0.001) but not (B) lipoprotein-associated phospholipase A2 (Lp-PLA2) mass o
TNF-alpha messenger ribonucleic acid (mRNA) was markedly induced but (D) Lp-PL
TNF-alpha but not of (F) Lp-PLA .2ctivity were normally distributed and, therefore, used as
utcomes, whereas CRP was log-transformed. The linear
egression model included adjustments for age, sex, and smok-
ng. Analysis used PLINK (version 1.06, Shaun Purcell,
oston, Massachusetts). Analyses of CAC and plasma pro-
eins were performed separately in each sample and then
ubjected to meta-analysis. Meta-analysis applied a weighted
-score method using METAL (Center for Statistical Genet-
cs, University of Michigan, Ann Arbor, Michigan) (22,23) as
e applied it in (24) as described in the Online Appendix. In
nalysis of SNP data, we corrected for the number of inde-
endent tests within each gene (10 tests for 19 PLA2G7 SNPs,
nadjusted p value threshold of 0.005, and 15 tests for 15 CRP
NPs, unadjusted p value threshold of 0.0033) using the
ethod of Nyholt (25).
esults
p-PLA2 is not induced in a human model of acute
phase response. As we described previously (13,26), endo-
toxemia produced an acute, febrile illness associated with a
marked, transient induction of plasma TNF-alpha (p 
0.001), followed by a delayed 100-fold induction of
plasma CRP at 24 h (p  0.001) (Fig. 1A). In contrast,
plasma Lp-PLA2 mass and activity did not increase follow-
ing LPS (Fig. 1B). Indeed, levels of Lp-PLA2 mass tended to
ecline (by 18% at 6 h, p  0.01). The mRNA response to
PS in whole blood for TNF-alpha (Fig. 1C) and Lp-PLA2
Protein or Leukocyte Lp-PLA2 mRNA In Vivo
a levels of (A) tumor necrosis factor (TNF)-alpha and C-reactive protein (CRP)
ity, which declined transiently (p  0.01). Following LPS, whole blood (C)
NA is not. Similarly, LPS increased circulating monocyte mRNA levels of (E)LA2
plasm
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February 21, 2012:764–72 Human Translation of Lp-PLA2(Fig. 1D), as well as in circulating monocytes for TNF-alpha
(Fig. 1E) and Lp-PLA2 (Fig. 1F), was similar to that of
lasma proteins. The mRNA levels of Lp-PLA2 in circulating
monocytes were low but detectable (baseline cycle threshold
[CTs] 30, varying from CTs of 28 to 32 post-LPS).
p-PLA2 expression is induced in inflammatory human
macrophages and foam cells. Lp-PLA2 mRNA levels were
low (CTs 30) in freshly isolated human monocytes but
increased markedly (CTs 20) following 6 days of differenti-
tion to mature macrophages (p  0.0001) (Fig. 2A) and
ncreased modestly during further polarization to M1 (p 
.0001) but not M2 macrophages (Fig. 2B). Lp-PLA2 protein
mass also was induced during differentiation to macrophages,
with increases in both the cell-associated protein (p 0.0001)
nd the secreted protein (p  0.0004) (Fig. 2C). Following
oading of human monocyte-derived macrophages with acety-
ated LDL-cholesterol for 48 h, cholesterol ester (128 vs. 0.6
g cholesterol ester /mg protein) and total cholesterol (422 vs.
316 g cholesterol/mg protein) were significantly higher in
loaded versus unloaded cells, which is consistent with findings
for in vivo foam cells (27). Lp-PLA2 mRNA levels were
ignificantly greater in foam cells than in mature macrophages
p 0.01) (Fig. 3A). Similarly, cell-associated (p 0.05) and
secreted (p  0.008) Lp-PLA2 protein levels were higher in
oam cells than in macrophages (Fig. 3B). There was no
p-PLA2 protein detectable in the media or acetylated LDL
sed to treat cells. Overall, these data are consistent with lack
f in vivo increase in plasma or monocyte levels of Lp-PLA2
during the acute phase and suggest that, in human atheroscle-
rosis, Lp-PLA2 may be generated by macrophages and foam
ells rather than by circulating leukocytes.
Exploratory interrogation of PLA2G7 SNP eQTLs for
Lp-PLA2 mRNA expression in publicly available data
evealed nominal associations of several SNPs in the
LA2G7 region with exon probe levels in peripheral blood
ononuclear cells (best p 0.0059, rs12181971) and brain (best
 0.008, rs12195701) (28), as well as skin (best p  0.021,
s16874962), fat (best p 0.019, rs16874962), and lymphoblas-
oid cells (best p  0.037, rs7745519) (MuTHER [Multiple
issue Human Expression Resource] twin2 study (29)). These
odest associations, however, were not significant after correction
or multiple testing (see the Online Appendix). Macrophage and
oam cell expression datasets were not available for testing a more
therosclerosis-relevant cell type.
ommon polymorphisms in PLA2G7 are associated with
oronary calcification but only weakly with plasma Lp-
LA2 mass or activity. Individually in SIRCA or PDHS
samples, there were no significant associations between
PLA2G7 SNPs and Lp-PLA2 mass or activity. In the
combined meta-analysis, only 1 SNP (rs1805017) had
nominal association with Lp-PLA2 mass (p  0.02; p  0.2
after Bonferroni correction) (Table 1A). As a positive control,
we performed similar analysis of plasma CRP using com-
mon CRP SNPs. In contrast to findings for PLA2G7-
Lp-PLA2, there were significant associations between nu-
merous CRP SNPs and plasma CRP in the SIRCA andPDHS samples and in the overall meta-analysis (Table 1B).
Of 16 CRP SNPs, 9 had nominal (p  0.05) associations
with CRP levels and 8 of these SNPs had significant
Figure 2
Lp-PLA2 mRNA and Protein
Increase During Differentiation of
Human Monocytes to Macrophages In Vitro
Lp-PLA2 mRNA levels increased markedly during differentiation from monocytes
to mature macrophages (p  0.0001) (A) and increased modestly during fur-
ther polarization to M1 macrophages (p  0.001) but fell during M2 polariza-
tion (p  0.001) (B). Lp-PLA2 protein mass also increased significantly during
differentiation to macrophages, with increases in both the cell-associated pro-
tein (p  0.0001) and the secreted protein (p  0.0004) (C). Note: As mono-
cytes were grown in suspension, protein levels were measured in monocyte
cell lysates but could not be measured in media. (Analysis of variance and
Bonferroni post hoc tests). Abbreviations as in Figure 1.associations after Bonferroni correction.
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Human Translation of Lp-PLA2 February 21, 2012:764–72Association of PLA2G7 SNPs with CAC was assessed
initially in SIRCA and PAMSyN together with follow-up
in PDHS. Multiple PLA2G7 SNPs had nominal associa-
tions with CAC in SIRCA and PAMSyN (11 with p 
0.05; lowest p  0.0001 for rs1421378). Replication signals
in PDHS were modest (strongest rs10948300, p  0.02)
ikely due to limited power; however, in PDHS, 16 of 19 SNPs
ad effects in the same direction as in SIRCA or PAMSyN
chi squared: 8.9, p  0.003). Meta-analysis of the combined
ample found several SNP associations with CAC (rs9349373,
 0.002; rs2216465, p 0.002; rs12195701, p 0.004) that
ere significant after Bonferroni correction (Table 2A). In-
luding plasma Lp-PLA2 mass or activity in the model did not
ttenuate the association between PLA2G7 SNPs and CAC.
hese findings support recent associations of variation in
LA2G7 with CHD (30–32).
As an expected negative control (14,33,34), we examined
Figure 3 Lp-PLA2 mRNA and Protein Are Up-Regulated
in Human Foamlike Cells In Vitro
Lp-PLA2 mRNA was significantly greater (p  0.01) in foam cells than in mature
macrophages (A). Similarly, cell-associated (p  0.05) and secreted (p 
0.008) Lp-PLA2 protein levels were higher in foam cells than in macrophages
(B). (Note: As monocytes were grown in suspension, protein levels were mea-
sured in monocyte cell lysates but could not be measured in media. (Analysis
of variance and Bonferroni post hoc tests). Abbreviations as in Figure 1.RP variant associations with CAC in the same sample andound minimal signal, with 1 SNP having nominal associ-
tion in SIRCA and PAMSyN (rs3093068, p  0.04);
owever, there were no associations in PDHS nor in
ombined meta-analysis.
iscussion
e provide novel insight into the pathophysiology of Lp-
LA2 in humans. First, we show that unlike TNF-alpha and
CRP, circulating Lp-PLA2 does not increase during experi-
mental endotoxemia and, therefore, does not contribute to
human acute phase response. Second, we found that inflam-
matory macrophages and foam cells, but not circulating mono-
cytes or cultured primary monocytes, generate significant
Lp-PLA2. This is consistent with the concept that the majority
f Lp-PLA2 in atherosclerotic plaque is derived from local
iosynthesis by inflammatory macrophage and foam cells
ather than from circulating leukocytes. Third, we found that
ommon variants in PLA2G7 are associated with CAC but had
imited relation to circulating Lp-PLA2 mass or activity. This
upports an atherogenic role for PLA2G7-Lp-PLA2 in hu-
mans that may be independent of circulating Lp-PLA2 mass
r activity.
p-PLA2 does not contribute to human acute phase
response. We demonstrate that Lp-PLA2 is not an acute
phase protein in humans. This is in contrast to rodent
models in which LPS challenge was shown to induce a rapid
increase in plasma and tissue levels of Lp-PLA2 (35). This
provides further evidence of fundamental differences be-
tween humans and rodents in the physiology and action of
Lp-PLA2 (36). Lack of induction in blood and circulating
onocytes by endotoxemia in vivo also suggests limited, if
ny, role for circulating leukocyte production of Lp-PLA2
in atherosclerosis. In contrast, marked in vitro up-regulation
in macrophages and foam cells is consistent with a specific
role for local vascular production of Lp-PLA2 in atheroscle-
osis. Although it is possible that local macrophage Lp-
LA2 production in plaque may contribute to a portion of
circulating Lp-PLA2, it is unlikely to render circulating
levels useful as independent biomarkers of Lp-PLA2 actions
in atherosclerosis because published data show that circu-
lating Lp-PLA2 mass and activity do not correlate with
laque Lp-PLA2 in patients undergoing elective carotid
ndarterectomy (37) and because there is substantial con-
ounding of plasma Lp-PLA2 by circulating lipoproteins
egardless of tissue source. Overall, these data suggest that
evels of Lp-PLA2 mRNA and protein in blood may be
poor surrogates of PLA2G7 actions in arterial plaque.
Proinflammatory macrophages and foam cells, but not
monocytes, generate significant Lp-PLA2. We found
hat Lp-PLA2 expression was markedly increased during
the differentiation of monocytes to macrophages, and fur-
ther induced in vitro in “foam cell–like macrophages. This is
consistent with constitutive expression and activity in in-
flammatory macrophages (38) and foam cells in atheroscle-
rosis. Indeed, Lp-PLA2 expression is increased in athero-
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February 21, 2012:764–72 Human Translation of Lp-PLA2sclerotic lesions in humans (10). In this environment,
secreted Lp-PLA2 can hydrolyze oxidized phospholipids
and fatty acids on atherogenic lipoproteins, generating
reactive lipid mediators thought to promote plaque in-
stability. Inhibition of Lp-PLA2 suppressed oxidized-
LDL–induced macrophage apoptosis (39), a feature of
inflammatory plaque. Further, in a porcine model of com-
plex atherosclerosis, suppression of Lp-PLA2 retarded ath-
rosclerosis progression and decreased plaque inflammation,
Lack of Association Between SNPs in PLA2G7 and Circulating Lp-PBut Significant Relation of Multiple SN s in CRP With Circulating CTable 1 Lack of Association B tween SNPs in PLA2G7 and CirBut Significant Relation of Multiple SNPs in CRP With
PLA2G7 SNP
(Allele: Minor/Major)† Type of SNP MAF
rs1805017 (A/G) Nonsynonymous coding 0.26
rs2216465 (C/G) Intronic 0.34
rs1421378 (G/A) Upstream 0.41
rs17288905 (G/A) Intronic 0.08
rs10948300 (T/A) Intronic 0.21
rs12195701 (A/G) Intronic 0.21
rs1051931 (A/G) Nonsynonymous coding 0.21
rs7756935 (C/A) Intronic 0.21
rs12528807 (C/A) Intronic 0.08
rs1362931 (A/C) Intronic 0.20
rs1421372 (A/G) Intronic 0.20
rs3799861 (A/G) Intronic 0.20
rs9472830 (A/G) Intronic 0.20
rs16874962 (A/G) Intronic 0.07
rs3799863 (A/T) Intronic 0.05
rs1421368 (G/A) Intronic 0.10
rs9349373 (A/G) Upstream 0.20
rs16874967 (A/G) Intronic 0.06
rs1805018 (G/A) Nonsynonymous coding 0.06
CRP SNP
(Allele: Minor/Major)†
rs1205 (A/G) 3’ UTR 0.34
rs1800947 (G/C) Synonymous coding 0.07
rs3091244 (A/G) 5’ upstream 0.37
rs12084589 (A/C) 5’ upstream 0.07
rs12068753 (A/T) 5’ upstream 0.07
rs3093059 (G/A) 5’ upstream 0.07
rs3093068 (G/C) 3’ downstream 0.06
rs2794521 (G/A) 5’ upstream 0.25
rs3093066 (A/C) 3’ UTR 0.001
rs2808634 (A/G) 5’ upstream 0.27
rs1130864 (A/G) 3’ UTR 0.30
rs2808631 (G/A) 3’ downstream 0.002
rs3093070 (C/A) 3’ downstream 0.02
rs3093069 (C/A) 3’ downstream 0.001
rs3093071 (A/C) 3’ downstream 0.01
The 19 SNPs in PLA2G7 fall into 10 LD blocks (r2 	 0.8); therefore, we used Bonferroni multiple
in CRP fall into 15 LD blocks (r2	 0.8); therefore, we used Bonferroni multiple testing correction fo
IRCA (Study of Inherited Risk of Coronary Atherosclerosis) and the PDHS (Penn Diabetes Heart S
LD  linkage disequilibrium; Lp-PLA2  lipoprotein-associated phospholipase A2; MAF  minoecrosis, and fibrous cap erosion (7). Compared with vlacebo, short-term Lp-PLA2 inhibition in humans also
educed several markers of plaque inflammation in carotid
esions examined ex vivo (5,6). Overall, these data provide
ndirect evidence for atherogenic actions of Lp-PLA2 in
ascular lesions. Indeed, Lp-PLA2 inhibition is currently
eing tested in large phase III clinical trials of CHD in
igh-risk patients (NCT01000727).
enetic variation inPLA2G7may relate toCHDindependent
f circulating Lp-PLA2. Several epidemiological studies re-
Protein Mass or ActivityLevels*ing Lp-PLA2 Protein Mass or Activity
lating CRP Levels*
Lp-PLA2 Mass Lp-PLA2 Activity
Meta-Analysis
(n  1,723)
Meta-Analysis
(n  1,683)
Z-Score p Value Z-Score p Value
2.34 0.02 0.23 0.82
1.54 0.12 0.66 0.51
1.37 0.17 0.37 0.71
1.74 0.08 0.79 0.43
1.77 0.08 0.31 0.76
1.46 0.14 0.77 0.44
1.53 0.13 0.07 0.95
1.53 0.13 0.07 0.95
–0.36 0.72 0.44 0.66
1.15 0.25 0.06 0.96
1.15 0.25 0.06 0.96
1.15 0.25 0.06 0.96
1.07 0.29 0.08 0.94
–1.12 0.26 –0.46 0.64
–0.71 0.48 1.01 0.31
0.42 0.68 0.02 0.99
0.23 0.82 –0.49 0.63
–0.34 0.74 0.68 0.49
–0.34 0.74 0.68 0.49
Meta-Analysis
(n  2,026)
Z-Score p Value
5.63 1.8 10–8
5.41 6.4 10–8
4.40 1.1 10–5
3.23 1.0 10–3
3.18 1.0 10–3
3.14 2.0 10–3
2.94 3.0 10–3
0.29 0.77
1.99 0.05
0.39 0.69
2.94 0.003
–1.49 0.14
–0.82 0.41
1.37 0.17
1.23 0.22
correction for 10 effective tests, giving a p value threshold of significance of 0.005. The 15 SNPs
fective tests, giving a p value threshold of significance of 0.0033. *Meta-analysis of data from the
†For all analyses, the effect allele corresponds to the minor allele.
frequency; SNP  single nucleotide polymorphism; UTR  untranslated region.LA2RPculat
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Human Translation of Lp-PLA2 February 21, 2012:764–72activity levels with risk of CHD (9,40–42). Meta-analyses
support a modest CHD relationship independent of tradi-
tional risk factors and plasma CRP (40,43,44). Published
studies, however, may underestimate the degree of con-
founding because of incomplete measurement and control
for all atherogenic lipoproteins (9). In circulation, Lp-PLA2
associates with apolipoprotein B and high-density lipopro-
teins, with the majority found on LDL particles. Because
Lp-PLA2 protein and activity are closely linked to circulat-
ing apolipoprotein B lipoproteins (36,45), it is not surpris-
ing that genetic factors (e.g., APOC1, PSRC1, ZNF259)
that regulate plasma apolipoprotein B lipoproteins are also
associated with plasma Lp-PLA2 (46). Parenthetically, we
Association of SNPs in PLA2G7 But Not in CRP With CACTable 2 Association of SNPs in PLA2G7 But Not in CRP With C
Type of SNP MAF
PLA2G7 SNP (allele: minor/major)*
rs1421378 (G/A) Upstream 0.41
rs2216465 (C/G) Intronic 0.34
rs12528807 (C/A) Intronic 0.08
rs9349373 (A/G) Upstream 0.20
rs10948300 (T/A) Intronic 0.21
rs1805017 (A/G) Nonsynonymous coding 0.26
rs3799863 (A/T) Intronic 0.05
rs16874967 (A/G) Intronic 0.06
rs1805018 (G/A) Nonsynonymous coding 0.06
rs12195701 (A/G) Intronic 0.21
rs1421368 (G/A) Intronic 0.10
rs9472830 (A/G) Intronic 0.20
rs1362931 (A/C) Intronic 0.20
rs1421372 (A/G) Intronic 0.20
rs3799861 (A/G) Intronic 0.20
rs7756935 (C/A) Intronic 0.21
rs1051931 (A/G) Nonsynonymous coding 0.21
rs16874962 (A/G) Intronic 0.07
rs17288905 (G/A) Intronic 0.084
CRP SNP (allele: minor/major)*
rs3093068 (G/C) 3’ downstream 0.06
rs3093059 (G/A) 5’ upstream 0.07
rs12068753 (A/T) 5’ upstream 0.07
rs12084589 (A/C) 5’ upstream 0.07
rs2808631 (G/A) 3’ downstream 0.002
rs1800947 (G/C) Synonymous coding 0.07
rs2794521 (G/A) 5’ upstream 0.25
rs1130864 (A/G) 3’ UTR 0.30
rs2808634 (A/G) 5’ upstream 0.27
rs3093071 (A/C) 3’ downstream 0.01
rs3093066 (A/C) 3’ UTR 0.001
rs3093069 (C/A) 3’ UTR 0.001
rs1205 (A/G) 3’ downstream 0.34
rs3093070 (C/A) 5’ upstream 0.02
rs3091244 (A/G) 3’ downstream 0.37
*For all analyses, the effect allele corresponds to the minor allele.
CAC coronary artery calcification; PAMSyN  Philadelphia Area Metabolic Syndrome Network
abbreviations as in Table 1.ound modest association of lipid-related genes (e.g., LRP2,PL, APOA2) with plasma Lp-PLA2 likely reflecting this
indirect post-translational influence (Online Tables 1A and
1B). Interpretation of studies of plasma Lp-PLA2 in CHD
is challenging partly because circulating lipoproteins may
grossly confound the association of plasma Lp-PLA2 with
HD (8) and furthermore because lesion macrophage
roduction may be more relevant to the disease than
irculating protein.
While we failed to detect significant association between
lasma Lp-PLA2 and common SNPs in PLA2G7, the same
PLA2G7 variants were associated with CAC within our
study samples. Our preliminary exploration also revealed
only nominal associations of PLA2G7 SNPs with Lp-PLA2
RCA and PAMSyN
(n  1,279)
PDHS
(n  782)
Meta-Analysis
(n  2,061)
a p Value Beta p Value Z Score p Value
1 9.8 10–5 0.05 0.65 3.35 8.1 10–4
9 3.9 10–4 0.05 0.67 3.06 0.002
9 0.004 0.40 0.07 3.36 7.7 10–4
6 0.008 0.22 0.13 3.04 0.002
4 0.013 0.32 0.02 3.36 7.8 10–4
2 0.014 0.09 0.49 2.37 0.018
6 0.016 –0.23 0.39 1.37 0.17
9 0.02 –0.14 0.56 1.41 0.16
9 0.02 –0.14 0.56 1.41 0.16
1 0.03 0.26 0.07 2.85 0.004
7 0.04 –0.17 0.37 –2.16 0.03
9 0.05 –0.16 0.23 –2.26 0.02
9 0.05 –0.16 0.23 –2.25 0.02
9 0.05 –0.16 0.23 –2.25 0.02
9 0.05 –0.16 0.23 –2.25 0.02
6 0.11 –0.15 0.25 –1.98 0.05
6 0.11 –0.16 0.23 –2.01 0.04
2 0.44 0.15 0.46 1.06 0.29
4 0.76 –0.02 0.94 –0.29 0.77
2 0.04 –0.09 0.70 –1.82 0.07
1 0.06 –0.11 0.65 –1.78 0.07
1 0.06 –0.08 0.75 –1.70 0.09
1 0.06 –0.05 0.83 –1.63 0.10
2 0.07 0.52 0.64 –1.16 0.25
9 0.23 0.29 0.18 1.77 0.08
1 0.23 0.01 0.93 –0.90 0.37
0 0.27 –0.15 0.21 0.10 0.92
9 0.30 0.00 0.98 –0.84 0.40
3 0.54 –0.21 0.67 –0.75 0.45
7 0.57 –1.52 0.33 –1.04 0.30
7 0.57 1.54 0.49 –0.01 0.99
4 0.65 0.16 0.17 1.20 0.23
3 0.69 –0.67 0.56 –0.22 0.50
9 0.99 0.00 0.15 –0.17 0.37
 Penn Diabetes Heart Study; SIRCA  Study of Inherited Risk of Coronary Atherosclerosis; otherAC
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power, relatively low levels of Lp-PLA2 expression in tested
ells, and (unlike CRP) well-characterized cis-acting SNPs
or PLA2G7 are lacking. Further, appropriately powered
tudies are needed to determine whether PLA2G7 SNPs are
elated to expression of Lp-PLA2 in inflammatory macro-
hages and foam cells, sources that may be most relevant to
therosclerosis. However, our data suggest caution in using
irculating leukocyte Lp-PLA2 mRNA levels as surrogates
for effects of PLA2G7 variation on arterial pathology.
Overall, our findings support the concept that PLA2G7 may
relate to atherosclerosis independent of circulating Lp-
PLA2 mRNA and protein.
Published studies of PLA2G7 in CHD are conflicting. In
a meta-analysis of individuals of European ancestry,
PLA2G7 SNPs did not associate with risk of CHD (n
5,000) (42), although there were relationships between
Lp-PLA2 activity and CHD and between PLA2G7 SNPs
nd Lp-PLA2 activity. However in a meta-analysis of over
13,000 Asians, a common nonsynonymous PLA2G7 SNP
showed evidence of association with CHD (31). Additional
nonsynonymous SNPs have been associated with carotid
plaque in Japanese (32) and recently a loss-of-function
variant in PLA2G7 was shown to protect against CHD in
Koreans (30). Due to the absence in Caucasian samples of
the functional PLA2G7 SNP found in Asians (rs76863441
or V279F), we were not able to evaluate the effect of this
functional variant in our samples. However, common vari-
ation in PLA2G7 is well covered on the ITMAT Broad
Care array platform (tag SNP-coverage r2 	0.8 for alleles
with minor allele frequency 2% in the gene  5 kilobases)
(21). Therefore, we are confident that we achieved excellent
coverage of common variation in this gene region in Cauca-
sians. Whereas ethnic difference in the presence of allelic
variation may exist, most published data suggest a relationship
of PLA2G7 with clinical CHD supporting our CAC findings.
Findings for CRP in our samples are consistent with
ublished data and contrast with that observed for
LA2G7-Lp-PLA2. Thus, even though a number of SNPs
in CRP had strong associations with circulating CRP levels,
there was no relationship between these same SNPs and
CAC. These data are in line with hallmark Mendelian
randomization studies of clinical CHD outcomes (33,34)
and support a model of confounding or reverse causation for
CRP associations with CAC and CHD.
Study limitations. First, our studies are correlative and do
not define causality. We have not studied loss-of-function
or gain-of-function variants in PLA2G7 for their relation to
CAC or CHD and, therefore, cannot infer Lp-PLA2
directional actions in atherosclerosis. However, expression
data in inflammatory macrophages and foam cells coupled
to preliminary studies of Lp-PLA2 inhibition in human
atherosclerosis support an atherogenic role for human
PLA2G7. Second, recent studies have shown stronger asso-
ciations of PLA2G7 with circulating Lp-PLA2 measures
than were found in our sample. This may relate to oursmaller sample size, heterogeneity in the SIRCA and
PDHS study samples, or differences in Lp-PLA2 assays
used across studies. The PLA2G7-Lp-PLA2 system, how-
ever, may be a poor target for Mendelian randomization
studies for several reasons including: heterogeneous envi-
ronmental and genetic influences on circulating levels;
PLA2G7 actions in atherosclerosis are likely to be indepen-
dent of circulating Lp-PLA2; and well-characterized cis-
acting SNPs to use as instrumental variables for PLA2G7
are lacking. Finally, although not a direct measure of
coronary atherosclerosis, studies show that CAC provides a
quantitative estimate of coronary atherosclerosis (47) and is
a useful predictor of CHD events (48).
Conclusions
We have demonstrated that Lp-PLA2, in contrast to CRP,
is not an acute phase protein in humans. Lp-PLA2 has
limited expression in circulating leukocytes or unstimulated
monocytes ex vivo, but it is induced during differentiation to
macrophages and in foam cells. Thus, robust biomarkers of
Lp-PLA2 action in atherosclerosis and of its pharmacolog-
cal modulation in vascular tissues are lacking. Common
ariation in PLA2G7, but not in CRP, is related to the
urden of CAC, suggesting that PLA2G7 may indeed
odulate human atherosclerosis. Our data provide support
or the atherogenicity of Lp-PLA2 in humans while high-
lighting the challenges in using plasma Lp-PLA2 as a
iomarker of CHD and in determining drug-dosing and
herapeutic efficacy in atherosclerosis.
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